These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1450 related articles for article (PubMed ID: 33907095)

  • 21. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
    Bhuiyan T; Helmke S; Patel AR; Ruberg FL; Packman J; Cheung K; Grogan D; Maurer MS
    Circ Heart Fail; 2011 Mar; 4(2):121-8. PubMed ID: 21191093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
    Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
    Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid detection of wild-type and mutated transthyretins.
    Tasaki M; Ueda M; Obayashi K; Motokawa H; Kinoshita Y; Suenaga G; Yanagisawa A; Toyoshima R; Misumi Y; Masuda T; Yamashita T; Ando Y
    Ann Clin Biochem; 2016 Jul; 53(Pt 4):508-10. PubMed ID: 26342004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
    Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
    J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
    Dahlem K; Michels G; Kobe C; Bunck AC; Ten Freyhaus H; Pfister R
    Clin Res Cardiol; 2017 Jun; 106(6):471-473. PubMed ID: 28303323
    [No Abstract]   [Full Text] [Related]  

  • 28. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative bone scintigraphy in wild-type transthyretin cardiac amyloidosis.
    Martini N; Rizzo S; Sarais C; Cipriani A
    BMC Cardiovasc Disord; 2020 Oct; 20(1):466. PubMed ID: 33121442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
    Gillmore JD; Maurer MS; Falk RH; Merlini G; Damy T; Dispenzieri A; Wechalekar AD; Berk JL; Quarta CC; Grogan M; Lachmann HJ; Bokhari S; Castano A; Dorbala S; Johnson GB; Glaudemans AW; Rezk T; Fontana M; Palladini G; Milani P; Guidalotti PL; Flatman K; Lane T; Vonberg FW; Whelan CJ; Moon JC; Ruberg FL; Miller EJ; Hutt DF; Hazenberg BP; Rapezzi C; Hawkins PN
    Circulation; 2016 Jun; 133(24):2404-12. PubMed ID: 27143678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
    Yamamoto H; Yokochi T
    ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
    Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
    Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
    Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy.
    Chimenti C; Alfarano M; Maestrini V; Galea N; De Vincentis G; Verardo R; Fedele F; Frustaci A
    ESC Heart Fail; 2021 Aug; 8(4):3387-3391. PubMed ID: 34032384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy.
    Iwaya T; Okada A; Tateishi E; Ohta Y; Morita Y; Ohta-Ogo K; Izumi C
    ESC Heart Fail; 2023 Apr; 10(2):1412-1417. PubMed ID: 36335980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.